Evidence map›Paper›PMID 38303564›Full record

ArticleBMB reports2024

Therapeutic potential of BMSC-conditioned medium in an in vitro model of renal fibrosis using the RPTEC/TERT1 cell line.

Yunji Kim, Dayeon Kang, Ga-Eun Choi, Sang Dae Kim, Sun-Ja Yang, Hyosang Kim, Dalsan You, Choung Soo Kim, Nayoung Suh

Open access · goldAbstract readNews
PubMed Full text at PMC
In one paragraph

Article in BMB reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yunji KimDepartment of Medical Sciences, General Graduate School, Soonchunhyang University, Asan 31538, Korea.
Dayeon KangDepartment of Medical Sciences, General Graduate School, Soonchunhyang University, Asan 31538, Korea; Department of Pharmaceutical Engineering, College of Medical Sciences, Soonchunhyang University, Asan 31538, Korea.
Ga-Eun ChoiDepartment of Medical Sciences, General Graduate School, Soonchunhyang University, Asan 31538, Korea.
Sang Dae KimDepartment of Medical Sciences, General Graduate School, Soonchunhyang University, Asan 31538, Korea.
Sun-Ja YangPharmicell Co., Ltd., Seongnam 13229, Korea.
Hyosang KimDivision of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Dalsan YouDepartment of Urology, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Choung Soo KimUrology Institute, Ewha Womans University Mokdong Hospital, Seoul 07985, Korea.
Nayoung SuhDepartment of Medical Sciences, General Graduate School, Soonchunhyang University, Asan 31538, Korea; Department of Pharmaceutical Engineering, College of Medical Sciences, Soonchunhyang University, Asan 31538, Korea.
Soonchunhyang University · KRUlsan College · KREwha Womans University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the therapeutic potential of bone marrow-derived mesenchymal stem cell-conditioned medium (BMSC-CM) on immortalized renal proximal tubule epithelial cells (RPTEC/ TERT1) in a fibrotic environment. To replicate the increased stiffness characteristic of kidneys in chronic kidney disease, we utilized polyacrylamide gel platforms. A stiff matrix was shown to increase α-smooth muscle actin (α-SMA) levels, indicating fibrogenic activation in RPTEC/TERT1 cells. Interestingly, treatment with BMSC-CM resulted in significant reductions in the levels of fibrotic markers (α-SMA and vimentin) and increases in the levels of the epithelial marker E-cadherin and aquaporin 7, particularly under stiff conditions. Furthermore, BMSC-CM modified microRNA (miRNA) expression and reduced oxidative stress levels in these cells. Our findings suggest that BMSC-CM can modulate cellular morphology, miRNA expression, and oxidative stress in RPTEC/TERT1 cells, highlighting its therapeutic potential in fibrotic kidney disease. [BMB Reports 2024; 57(2): 116-121].

Indexed as

Kidney DiseasesMicroRNAsCell LineCulture Media, ConditionedFibrosisHumansCulture Media, ConditionedMicroRNAs

Identifiers

PMID38303564
PMCPMC10910087
OpenAlexW4392391782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.